|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:dateCreated |
2010-12-20
|
|
pubmed:abstractText |
Adenosine A(?A) receptor antagonism provides a promising approach to developing nondopaminergic therapy for Parkinson's disease (PD). Clinical trials of A(?A) antagonists have targeted PD patients with L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesia (LID) in an effort to improve parkinsonian symptoms. The role of adenosine in the development of LID is little known, especially regarding its actions via A? receptors. We aimed to examine the effects of genetic deletion and pharmacological blockade of A? and/or A(?A) receptors on the development of LID, on the induction of molecular markers of LID including striatal preprodynorphin and preproenkephalin (PPE), and on the integrity of dopaminergic nigrostriatal neurons in hemiparkinsonian mice. Following a unilateral 6-hydroxydopamine lesion A?, A(?A) and double A?-A(?A) knockout (KO) and wild-type littermate mice, and mice pretreated with caffeine (an antagonist of both A? and A(?A) receptors) or saline were treated daily for 18-21 days with a low dose of L-DOPA. Total abnormal involuntary movements (AIMs, a measure of LID) were significantly attenuated (p<0.05) in A? and A(?A) KOs, but not in A?-A(?A) KOs and caffeine-pretreated mice. An elevation of PPE mRNA ipsilateral to the lesion in WT mice was reduced in all KO mice. In addition, neuronal integrity assessed by striatal dopamine content was similar in all KOs and caffeine-pretreated mice following 6-hydroxydopamine lesioning. Our findings raise the possibility that A? or A(?A) receptors blockade might also confer a disease-modifying benefit of reduced risk of disabling LID, whereas the effect of their combined inactivation is less clear.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Adrenergic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Antiparkinson Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Caffeine,
http://linkedlifedata.com/resource/pubmed/chemical/Dynorphins,
http://linkedlifedata.com/resource/pubmed/chemical/Enkephalins,
http://linkedlifedata.com/resource/pubmed/chemical/Levodopa,
http://linkedlifedata.com/resource/pubmed/chemical/Oxidopamine,
http://linkedlifedata.com/resource/pubmed/chemical/Protein Precursors,
http://linkedlifedata.com/resource/pubmed/chemical/Purinergic P1 Receptor Antagonists,
http://linkedlifedata.com/resource/pubmed/chemical/RNA, Messenger,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, Adenosine A1,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, Adenosine A2A,
http://linkedlifedata.com/resource/pubmed/chemical/pre-prodynorphin,
http://linkedlifedata.com/resource/pubmed/chemical/preproenkephalin
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
1872-6240
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright © 2010 Elsevier B.V. All rights reserved.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
7
|
|
pubmed:volume |
1367
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
310-8
|
|
pubmed:dateRevised |
2011-10-5
|
|
pubmed:meshHeading |
pubmed-meshheading:20828543-Adrenergic Agents,
pubmed-meshheading:20828543-Animals,
pubmed-meshheading:20828543-Antiparkinson Agents,
pubmed-meshheading:20828543-Caffeine,
pubmed-meshheading:20828543-Corpus Striatum,
pubmed-meshheading:20828543-Disease Models, Animal,
pubmed-meshheading:20828543-Dynorphins,
pubmed-meshheading:20828543-Dyskinesia, Drug-Induced,
pubmed-meshheading:20828543-Enkephalins,
pubmed-meshheading:20828543-Gene Expression Regulation,
pubmed-meshheading:20828543-Levodopa,
pubmed-meshheading:20828543-Mice,
pubmed-meshheading:20828543-Mice, Inbred C57BL,
pubmed-meshheading:20828543-Mice, Knockout,
pubmed-meshheading:20828543-Oxidopamine,
pubmed-meshheading:20828543-Parkinson Disease,
pubmed-meshheading:20828543-Protein Precursors,
pubmed-meshheading:20828543-Purinergic P1 Receptor Antagonists,
pubmed-meshheading:20828543-RNA, Messenger,
pubmed-meshheading:20828543-Receptor, Adenosine A1,
pubmed-meshheading:20828543-Receptor, Adenosine A2A,
pubmed-meshheading:20828543-Statistics, Nonparametric,
pubmed-meshheading:20828543-Time Factors
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Deletion of adenosine A? or A(?A) receptors reduces L-3,4-dihydroxyphenylalanine-induced dyskinesia in a model of Parkinson's disease.
|
|
pubmed:affiliation |
MassGeneral Institute for Neurolodegenerative Disease, Department of Neurology, Massachusetts General Hospital, Charlestown, MA, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, Non-P.H.S.,
Research Support, Non-U.S. Gov't,
Research Support, N.I.H., Extramural
|
